Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 54Breast Neoplasms 37Fallopian Tube Neoplasms 22Multiple Myeloma 19Carcinoma, Ovarian Epithelial 15Neoplasms 12Lymphoma 10Triple Negative Breast Neoplasms 7Neoplasm Metastasis 6Lymphoma, Large B-Cell, Diffuse 6Recurrence 5Hodgkin Disease 4Breast Neoplasms, Male 4Solid Tumors 3Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Anaplastic 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Sarcoma 2Peritoneal Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × liposomal doxorubicin × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡